Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Bausch + Lomb makes its stock market debut

By Brian Buntz | May 6, 2022

Bauch + LombAfter Bausch Health (NYSE:BHC) spun out its eye care unit Bausch + Lomb Corp. (NYSE/TSX:BLCO), its stock dipped 4.3% to $16.04 while BLCO shares increased 8.11% to $20.00 from a starting price of $18.00 per share.

The $18 price tag was short of Wall Street’s expectations.

The initial public offering was one of the first in recent memory as the stock market has navigated mostly choppy waters since the beginning of 2022.

“Bausch + Lomb has long been associated with many of the most significant advances in eye health, and I am honored to work alongside our 12,000 global employees as we continue to focus on achieving our ongoing mission of helping people see better to live better all over the world,” said Joseph C. Papa, chairman and CEO, Bausch + Lomb.

Papa will serve as chairman and CEO of the company.

Bausch + Lomb has a portfolio of more than 400 products, including ophthalmic pharmaceuticals, contact lenses and other eye care products.

Founded in 1853 in Rochester, New York, Bausch + Lomb initially sold monocles and eyeglass frames.

Bausch + Lomb eventually became a publicly-traded company until 2013, when Valeant Pharmaceuticals acquired the firm for $8.57 billion. Valeant would later rebrand as Bausch Health Companies.

In 2021, Bausch Health generated $8.4 billion in overall revenue.

Bausch Health announced its intent to spin off its Bausch + Lomb brand in August 2020, explaining that it would free the company to focus on gastroenterology, aesthetics/dermatology, neurology and international pharma.

Bausch + Lomb will be headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Seagen
Seagen CEO Siegall resigns after domestic abuse arrest
Moderna
Moderna’s new CFO leaves after former employer discloses investigation
Pfizer logo
Pfizer to shell out $11.6B for migraine drugmaker Biohaven
Novartis logo
Novartis temporarily halts production of two radioligand therapy medicines

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards